The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Likelihood of American medical oncologists (AMOs) to order molecular testing before prescribing first-line therapy in patients with stage IV lung adenocarcinoma (l-ACA).
M. R. Green
No relevant relationships to disclose
A. J. Wozniak
No relevant relationships to disclose
S. L. Britton
No relevant relationships to disclose
J. Willey
No relevant relationships to disclose
K. E. Lemke
No relevant relationships to disclose
B. Tiscione
No relevant relationships to disclose
T. McGee
No relevant relationships to disclose
H. J. West
No relevant relationships to disclose